Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

BACKGROUND: Nexvax2® is a novel, peptide-based, epitope-specific immunotherapy intended to be administered by regular injections at dose levels that increase the threshold for clinical reactivity to natural exposure to gluten and ultimately restore tolerance to gluten in patients with celiac disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Daveson, A. James M., Ee, Hooi C., Andrews, Jane M., King, Timothy, Goldstein, Kaela E., Dzuris, John L., MacDougall, James A., Williams, Leslie J., Treohan, Anita, Cooreman, Michael P., Anderson, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832635/
https://www.ncbi.nlm.nih.gov/pubmed/29191561
http://dx.doi.org/10.1016/j.ebiom.2017.11.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832635/
https://www.ncbi.nlm.nih.gov/pubmed/29191561
http://dx.doi.org/10.1016/j.ebiom.2017.11.018

Ejemplares similares